Marine Petroleum Trust About To Put More Money In Your Pocket (MARPS)

Looking at the universe of stocks we cover at Dividend Channel, on 5/29/13, Marine Petroleum Trust (MARPS) will trade ex-dividend, for its quarterly dividend of $0.3946, payable on 6/28/13. As a percentage of MARPS's recent stock price of $16.91, this dividend works out to approximately 2.33%, so look for shares of Marine Petroleum Trust to trade 2.33% lower — all else being equal — when MARPS shares open for trading on 5/29/13.

START SLIDESHOW:
Click here to learn which 25 S.A.F.E. dividend stocks should be on your radar screen »

Below is a dividend history chart for MARPS, showing historical dividends prior to the most recent $0.3946 declared by Marine Petroleum Trust:

MARPS+Dividend+History+Chart

In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from MARPS is likely to continue, and whether the current estimated yield of 9.33% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of MARPS shares, versus its 200 day moving average:

Marine Petroleum Trust 200 Day Moving Average Chart

Looking at the chart above, MARPS's low point in its 52 week range is $11.72 per share, with $26.00 as the 52 week high point — that compares with a last trade of $16.91.

In Tuesday trading, Marine Petroleum Trust shares are currently up about 1.3% on the day.

null

More from Stocks

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Spotify Announces Major Upgrade to Free Mobile App

Spotify Announces Major Upgrade to Free Mobile App

Looks like Coca-Cola's M&A Strategy Is Paying Off

Looks like Coca-Cola's M&A Strategy Is Paying Off

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug